Market open
Kymera Therapeutic/$KYMR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kymera Therapeutic
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Ticker
$KYMR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
188
Website
KYMR Metrics
BasicAdvanced
$2.2B
-
-$2.98
2.19
-
Price and volume
Market cap
$2.2B
Beta
2.19
52-week high
$51.84
52-week low
$29.07
Average daily volume
622K
Financial strength
Current ratio
7.53
Quick ratio
7.226
Long term debt to equity
8.933
Total debt to equity
10.503
Interest coverage (TTM)
-1,030.96%
Management effectiveness
Return on assets (TTM)
-20.65%
Return on equity (TTM)
-36.38%
Valuation
Price to revenue (TTM)
53.04
Price to book
2.58
Price to tangible book (TTM)
2.58
Price to free cash flow (TTM)
-12.042
Growth
Revenue change (TTM)
-40.11%
Earnings per share change (TTM)
18.47%
3-year revenue growth (CAGR)
-13.54%
3-year earnings per share growth (CAGR)
12.62%
What the Analysts think about KYMR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Kymera Therapeutic stock.
KYMR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
KYMR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
KYMR News
AllArticlesVideos
Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 weeks ago
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
GlobeNewsWire·2 weeks ago
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Kymera Therapeutic stock?
Kymera Therapeutic (KYMR) has a market cap of $2.2B as of March 12, 2025.
What is the P/E ratio for Kymera Therapeutic stock?
The price to earnings (P/E) ratio for Kymera Therapeutic (KYMR) stock is 0 as of March 12, 2025.
Does Kymera Therapeutic stock pay dividends?
No, Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders as of March 12, 2025.
When is the next Kymera Therapeutic dividend payment date?
Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders.
What is the beta indicator for Kymera Therapeutic?
Kymera Therapeutic (KYMR) has a beta rating of 2.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.